Bleeding risk after kidney biopsy with platelet inhibition
Nephrology Dialysis Transplantation · 13.06.2026
DOI: 10.1093/ndt/gfag139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 13.06.2026. Verfasst von Daniel Kraus und 7 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Medicine - Nephrology, Rheumatology, and Kidney Transplantation, Johannes Gutenberg University Medical Center, 55131 Mainz, Germany. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Department of Nephrology at Mainz University Medical Center.
Abstract (Originalsprache)
Background and hypothesis Platelet inhibitor therapy is a relative contraindication to percutaneous kidney biopsies due to concerns about bleeding risk. Here, we present an analysis of a prospective observational study on the risk of complications after native and transplant kidney biopsies with and without platelet inhibition.
Methods
In this study, 1103 consecutive biopsies between 2020 and 2025 at a single tertiary academic care center were included (26.0% in transplanted kidneys). Complications after biopsy were assessed and recorded before discharge, which was the day after the biopsy unless complications occurred. The primary outcome was serious complications, defined as any unplanned procedures or prolongation of the hospital stay. Secondary outcomes included hematuria, hematoma, placement of a Foley catheter, arteriovenous fistula, X-ray imaging, radiological intervention to stop bleeding, and transfusion. Bleeding was also classified according to the criteria of the International Society on Thrombosis and Hemostasis and Bleeding Academic Research Consortium.
Results
Of total biopsies, 43.0% were performed in women, and 13.0% with continued platelet inhibition. Serious complications occurred in 4.3% of cases: native kidney biopsies, 5.0% versus transplant biopsies, 2.1% (log odds ratio, −0.91; 95% confidence interval, −1.9 to −0.11; P = .040). Transfusion was required in 1.8% of cases. Female sex, right-lateral position, and native kidney biopsy were associated with complications. In multivariable logistic regression analysis, platelet inhibition was not associated with increased risk of serious complications (log odds ratio, −0.23; 95% confidence interval, −1.7 to 0.87; P = .7). The risk of transfusion was associated with low hemoglobin before biopsy, hematuria before biopsy, and biopsies performed with the patient sitting, but not platelet inhibition in multivariable regression. No patient died of a complication.
Conclusion
Platelet inhibition is not statistically associated with increased risk of serious complications after kidney biopsy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1st Department of Medicine - Nephrology, Rheumatology, and Kidney Transplantation, Johannes Gutenberg University Medical Center, 55131 Mainz, Germany.
ORCID-Profile: Julia Weinmann-Menke
Förderung
- Department of Nephrology at Mainz University Medical Center
Zitieren
APA
Kraus, D., Sadek, R., Kommer, A., Claßen, P., Stortz, M., Holtz, S., Weber, S., & Weinmann-Menke, J. (2026). Bleeding risk after kidney biopsy with platelet inhibition. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag139
Vancouver
Kraus D, Sadek R, Kommer A, Claßen P, Stortz M, Holtz S, et al. Bleeding risk after kidney biopsy with platelet inhibition. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag139
BibTeX
@article{Kraus2026,
author = {Kraus, Daniel and Sadek, Razan and Kommer, Andreas and Claßen, Paul and Stortz, Marco and Holtz, Stefan and Weber, Simone and Weinmann-Menke, Julia},
title = {Bleeding risk after kidney biopsy with platelet inhibition},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag139}
}
EUVIMED